AN2 Therapeutics (NASDAQ: ANTX) director sells 35K shares via 10b5-1 plan

Q: At what prices were the ANTX shares sold in the latest Form 4 filing?

The reported ANTX share sales occurred at a weighted average price of $6.0082 , with individual transactions between $6.00 and $6.07 per share. The filer notes that full trade-by-trade price details are available to the issuer, security holders, or SEC staff upon request.

Q: Who actually holds the ANTX shares involved in the insider sales reported by Robin Shane Readnour?

The sold ANTX shares are held by MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP . Their general partner, MGC Venture Partners 2018 GP, LLC, has shared voting and dispositive power, and Readnour is a managing partner, with beneficial ownership only to her pecuniary interest.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. (ANTX) director Robin Shane Readnour reported indirect sales of common stock on August 17, 2026 through investment partnerships MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP under pre-arranged Rule 10b5-1 trading plans. A total of 35,402 shares of ANTX common stock were sold in open-market or private transactions at a weighted average price of $6.0082 per share, with individual trades ranging from $6.00 to $6.07. Readnour is a managing partner of MGC Venture Partners 2018 GP, LLC, which has shared voting and dispositive power over the partnerships’ holdings, and disclaims beneficial ownership of these securities except to the extent of her pecuniary interest. Separately, she reports 9,077 shares of ANTX common stock held directly.

Insider Trade Summary 10b5-1

Net Seller: 35,402 shares

Net Sell 3 txns

Insider Readnour Robin Shane

Role Director

Sold 35,402 shs ($213K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F3, F4, F5}	16,696	$6.0082	$100K
Sale	Common Stock ^{F2, F3, F4, F6}	18,706	$6.0082	$112K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 633,867 shares (Indirect, See footnotes); Common Stock — 9,077 shares (Direct)

Footnotes (6)

F1. The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026.
F2. The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026.
F3. Represents the weighted average sale price for multiple transactions ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.
F4. MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
F5. Shares held directly by MGC 2018 LP.
F6. Shares held directly by MGC 2018 QP.

Key Figures

Shares sold via MGC 2018 LP: 16,696 shares Shares sold via MGC 2018 QP: 18,706 shares Total shares sold: 35,402 shares +2 more

5 metrics

Shares sold via MGC 2018 LP 16,696 shares Indirect sale of ANTX common stock on August 17, 2026

Shares sold via MGC 2018 QP 18,706 shares Indirect sale of ANTX common stock on August 17, 2026

Total shares sold 35,402 shares Aggregate ANTX common stock sold indirectly on August 17, 2026

Weighted average sale price $6.0082 per share Weighted average for trades ranging from $6.00 to $6.07

Direct holdings after transaction 9,077 shares ANTX common stock held directly by Robin Shane Readnour

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, shared dispositive power, beneficial ownership

4 terms

Rule 10b5-1 trading plan regulatory

"The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price for multiple transactions ranging"

shared dispositive power financial

"MGC 2018 GP has shared voting and shared dispositive power over the shares"

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of the securities, except"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

What insider stock transactions did AN2 Therapeutics (ANTX) report for Robin Shane Readnour?

AN2 Therapeutics reported that director Robin Shane Readnour was associated with sales of 35,402 ANTX shares on August 17, 2026. The shares were sold indirectly through affiliated investment partnerships under Rule 10b5-1 trading plans at a weighted average price of $6.0082 per share.

At what prices were the ANTX shares sold in the latest Form 4 filing?

The reported ANTX share sales occurred at a weighted average price of $6.0082, with individual transactions between $6.00 and $6.07 per share. The filer notes that full trade-by-trade price details are available to the issuer, security holders, or SEC staff upon request.

How many ANTX shares did Robin Shane Readnour sell indirectly on August 17, 2026?

On August 17, 2026, entities associated with director Robin Shane Readnour sold 35,402 shares of ANTX common stock. The sales were split into 16,696 shares via MGC Venture Partners 2018, LP and 18,706 shares via MGC Venture Partners QP 2018, LP.

Were the recent ANTX insider sales by Robin Shane Readnour under a Rule 10b5-1 plan?

Yes. The filing states the ANTX share sales occurred automatically under Rule 10b5-1 trading plans adopted by MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP on April 23, 2026. Such plans pre-schedule trades, limiting the significance of trade timing as a sentiment signal.

Does Robin Shane Readnour still hold ANTX shares after the reported transactions?

Yes. After the reported transactions, Robin Shane Readnour reports 9,077 ANTX shares of common stock held directly. She is also associated with partnership holdings where she has shared voting and dispositive power but disclaims beneficial ownership beyond her pecuniary interest.

Who actually holds the ANTX shares involved in the insider sales reported by Robin Shane Readnour?

The sold ANTX shares are held by MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP. Their general partner, MGC Venture Partners 2018 GP, LLC, has shared voting and dispositive power, and Readnour is a managing partner, with beneficial ownership only to her pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/19/2026 - 05:59 PM Accepted by SEC EDGAR 08/19/2026 - 05:58 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Readnour Robin Shane

(Last)

(First)

(Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK

CALIFORNIA

94025

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/17/2026		S⁽¹⁾		16,696	D	$6.0082⁽³⁾	565,592	I	See footnotes⁽⁴⁾⁽⁵⁾
Common Stock	08/17/2026		S⁽²⁾		18,706	D	$6.0082⁽³⁾	633,867	I	See footnotes⁽⁴⁾⁽⁶⁾
Common Stock								9,077	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026.

2. The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026.

3. Represents the weighted average sale price for multiple transactions ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.

4. MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.

5. Shares held directly by MGC 2018 LP.

6. Shares held directly by MGC 2018 QP.

	/s/ Eric Easom, Attorney-in-Fact for Robin Shane Readnour	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR